Editorials

Monoclonal antibodies for migraine prevention: hope, hype, and health economy challenge

David Kernick
British Journal of General Practice 2020; 70 (697): e523-e524. DOI: https://doi.org/10.3399/bjgp20X711833

Article Information

vol. 70 no. 697 e523-e524
DOI 
https://doi.org/10.3399/bjgp20X711833
PubMed 
32732219
Published By 
Royal College of General Practitioners
Print ISSN 
0960-1643
Online ISSN 
1478-5242
History 
  • Published online July 30, 2020.
Copyright & Usage 
© British Journal of General Practice 2020

Author Information

  1. David Kernick, GP
  1. Exeter Headache Clinic, St Thomas’s Health Centre, Exeter, UK.
  1. ADDRESS FOR CORRESPONDENCE David Kernick
    Exeter Headache Clinic, St Thomas’s Health Centre, Exeter EX4 1HJ, UK. Email: David.kernick{at}nhs.net
View Full Text

Article usage

Article usage: July 2020 to December 2020

AbstractFullPdf
Jul 20208131
Aug 20207291414
Sep 202012683
Oct 20208152
Nov 20207200
Dec 20205142

Statistics from Altmetric.com

Back to top

In this issue

British Journal of General Practice: 70 (697)
British Journal of General Practice
Vol. 70, Issue 697
August 2020
Download PDF
Article Alerts
Email Article
Citation Tools

Monoclonal antibodies for migraine prevention: hope, hype, and health economy challenge
David Kernick
British Journal of General Practice 2020; 70 (697): e523-e524. DOI: 10.3399/bjgp20X711833
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement

 
 

British Journal of General Practice